| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
N-Methyl-DL-glutamic acid does not have a specific defined biological target. As a derivative of glutamic acid, it may interact with glutamate receptors or transporters, but its primary use is as a research tool. It is a cytotoxic analog of L-glutamic acid and can be used to study the effects of glutamic acid modification on cellular metabolism and enzyme activity. It is an endogenous metabolite.
|
|---|---|
| ln Vitro |
In vitro, N-Methyl-DL-glutamic acid is a cytotoxic analog of L-glutamic acid. It is used in biochemical investigations to probe enzyme substrate specificity and explore metabolic pathways. The compound's cytotoxic effects make it useful for studying the role of glutamic acid in cellular processes. However, specific IC50 values or detailed pharmacological data are not available in the public domain.
|
| ln Vivo |
In vivo data for N-Methyl-DL-glutamic acid are not extensively documented. As a cytotoxic analog of glutamic acid, it may have potential toxic effects if administered systemically. The compound is primarily used as a research tool for in vitro studies. It is not used as a therapeutic agent.
|
| Enzyme Assay |
In vitro enzyme assays may use N-Methyl-DL-glutamic acid as a substrate or inhibitor to study the specificity of enzymes that act on glutamic acid, such as glutamine synthetase or glutamate dehydrogenase. The compound's modified structure allows researchers to probe enzyme substrate specificity. Cytotoxicity assays can be performed in cell lines to assess its effects on cell viability.
|
| Cell Assay |
Cell-based assays for N-Methyl-DL-glutamic acid are conducted to assess its cytotoxic effects. Cells are treated with the compound at various concentrations, and cell viability is measured using MTT or similar assays. The compound can be used to study the role of glutamic acid metabolism in cellular functions. Specific protocols are not extensively documented.
|
| Animal Protocol |
In vivo animal experiments with N-Methyl-DL-glutamic acid are not documented, as the compound is a research reagent and not a therapeutic agent. Its cytotoxic effects would likely limit its in vivo applicability. The compound is primarily used for in vitro studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of N-Methyl-DL-glutamic acid are not characterized, as it is not a therapeutic agent. The compound has a molecular formula of C6H11NO4 and a molecular weight of 161.16. It is soluble in water (62.5 mg/mL). Storage: powder at -20°C for 3 years; in solvent at -80°C for 6 months.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for N-Methyl-DL-glutamic acid are limited. As a cytotoxic analog of glutamic acid, it may be toxic at high concentrations. The compound is for research use only and is not for human therapeutic use. Standard laboratory safety precautions should be followed. No specific toxicity data are available.
|
| References | |
| Additional Infomation |
N-methyl-DL-glutamic acid is a derivative of glutamic acid.
N-Methyl-DL-glutamic acid has CAS number 35989-16-3, molecular formula C6H11NO4, and molecular weight 161.16. It is an N-methylated derivative of glutamic acid and a cytotoxic analog. It is used in biochemical investigations. Purity: typically ≥98%. Not for human use; for research purposes only. |
| Molecular Formula |
C6H11NO4
|
|---|---|
| Molecular Weight |
161.15584
|
| Exact Mass |
197.045
|
| CAS # |
35989-16-3
|
| PubChem CID |
268779
|
| Appearance |
White to off-white solid powder
|
| Density |
1.278g/cm3
|
| Boiling Point |
330.2ºC at 760mmHg
|
| Flash Point |
153.5ºC
|
| Index of Refraction |
1.491
|
| LogP |
-3
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
11
|
| Complexity |
157
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
XLBVNMSMFQMKEY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C6H11NO4/c1-7-4(6(10)11)2-3-5(8)9/h4,7H,2-3H2,1H3,(H,8,9)(H,10,11)
|
| Chemical Name |
2-(methylamino)pentanedioic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ~62.5 mg/mL (~387.81 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.2050 mL | 31.0251 mL | 62.0501 mL | |
| 5 mM | 1.2410 mL | 6.2050 mL | 12.4100 mL | |
| 10 mM | 0.6205 mL | 3.1025 mL | 6.2050 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
